JONES FINANCIAL COMPANIES LLLP
Position in BCRX — Biocryst Pharmaceuticals Inc
CIK 815917
DES PERES, MO
Position in BCRX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$178,940
+$18,224 QoQ
Shares Held
17,894
+6.0% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#212
of 316 holders
Holding Since
Mar 2022
8 quarters on record
Voting authority
Sole 94%
Shared 0%
None 6%
Common Shares in BCRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026JONES FINANCIAL COMPANIES LLLP holds $116,301,284 across 50 Drug Manufacturers - Specialty & Generic names. BCRX ranks #16 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HLN |
Haleon plc
|
7,116,095 | $66,393,166 | |
| 2 | ZTS |
Zoetis Inc.
|
191,729 | $13,777,645 | |
| 3 | TEVA |
Teva Pharmaceutical Industries Ltd
|
332,250 | $11,256,629 | |
| 4 | PBH |
Prestige Consumer Healthcare Inc.
|
179,743 | $8,496,451 | |
| 5 | NBIX |
Neurocrine Biosciences Inc
|
33,495 | $5,645,247 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
4,777 | $2,588,321 | |
| 7 | VTRS |
Viatris Inc
|
136,476 | $2,167,238 | |
| 8 | AMRX |
Amneal Pharmaceuticals, Inc.
|
110,479 | $1,912,391 |
All Filings in BCRX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $178,940 | 17,894 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $160,716 | 16,882 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $17,160 | 2,200 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $11,255 | 1,483 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $10,752 | 1,200 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $9,375 | 1,250 | Shares | Sole | 2025-05-28 | |
| 2024-12-31 | $1,504 | 200 | Shares | Sole | 2025-02-06 | |
| 2022-03-31 | $6,504 | 400 | Shares | Sole | 2022-05-02 | |
| No filing history on record for this holder in this stock. | ||||||